Personalis Price to Book Ratio 2018-2026 | PSNL
Historical price to book ratio values for Personalis (PSNL) over the last 10 years. The current price to book ratio for Personalis as of May 11, 2026 is 2.05.
| Personalis Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-05-11 | 5.78 | 0.00 | |
| 2026-03-31 | 6.37 | 0.00 | |
| 2025-12-31 | 7.96 | 0.00 | |
| 2025-09-30 | 6.52 | $1.93 | 3.38 |
| 2025-06-30 | 6.56 | $2.15 | 3.05 |
| 2025-03-31 | 3.51 | $2.35 | 1.50 |
| 2024-12-31 | 5.78 | $2.38 | 2.43 |
| 2024-09-30 | 5.38 | $2.36 | 2.28 |
| 2024-06-30 | 1.17 | $2.12 | 0.55 |
| 2024-03-31 | 1.49 | $2.35 | 0.63 |
| 2023-12-31 | 2.10 | $2.56 | 0.82 |
| 2023-09-30 | 1.21 | $3.09 | 0.39 |
| 2023-06-30 | 1.88 | $3.63 | 0.52 |
| 2023-03-31 | 2.76 | $4.14 | 0.67 |
| 2022-12-31 | 1.98 | $4.67 | 0.42 |
| 2022-09-30 | 2.97 | $5.27 | 0.56 |
| 2022-06-30 | 3.45 | $5.77 | 0.60 |
| 2022-03-31 | 8.19 | $6.34 | 1.29 |
| 2021-12-31 | 14.27 | $6.91 | 2.07 |
| 2021-09-30 | 19.24 | $7.28 | 2.64 |
| 2021-06-30 | 25.30 | $7.66 | 3.30 |
| 2021-03-31 | 24.61 | $7.96 | 3.09 |
| 2020-12-31 | 36.61 | $4.99 | 7.34 |
| 2020-09-30 | 21.67 | $5.25 | 4.13 |
| 2020-06-30 | 12.97 | $2.92 | 4.44 |
| 2020-03-31 | 8.07 | $3.15 | 2.56 |
| 2019-12-31 | 10.90 | $3.41 | 3.19 |
| 2019-09-30 | 14.68 | $3.58 | 4.10 |
| 2019-06-30 | 27.15 | $3.76 | 7.22 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.630B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |